<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20160">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097511</url>
  </required_header>
  <id_info>
    <org_study_id>DDI-102</org_study_id>
    <nct_id>NCT02097511</nct_id>
  </id_info>
  <brief_title>Sarpogrelate Drug Interaction</brief_title>
  <official_title>A Randomized, Open-label, Three-sequence, Three-period Crossover Study to Investigate The Effect of Anplag on the Disposition of Betaloc in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single &amp; multiple-dose, three-sequence, three-period
      crossover study to investigate the effect of sarpogrelate hydrochloride on the disposition
      of metoprolol tartrate in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility for participation of this study will be determined from demographic information,
      medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests
      within 4 weeks before study drug administration. Subjects suitable for this study will be
      admitted to the Clinical Trial Center of Ajou University Medical Center on the day before
      dosing (Day -1).

      On Day 1, Subjects will be dosed study drug (metoprolol tartrate 100 mg once a day only, or
      metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a
      day, sarpogrelate hydrochloride 100 mg three times a day pretreatment for three days and
      metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a
      day).

      Pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12
      hours after metoprolol tartrate 100 mg dosing.

      After one week of washout period (Day 8), Subjects will be dosed study drug by crossover
      manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done
      upto 12 hours after metoprolol tartrate 100 mg dosing.

      After one week of washout period (Day 15), Subjects will be dosed study drug by crossover
      manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done
      upto 12 hours after metoprolol tartrate 100 mg dosing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma concentration of Metoprolol and metabolites</measure>
    <time_frame>upto 12 hours after Metoprolol Tartrate 100 mg dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax (maximal plasma concentration) and AUC (area under the time-concentration curve) will be calculated from pharmacokinetic samplings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and pulse rate changes</measure>
    <time_frame>Upto 12 hours after Metoprolol Tartrate 100 mg dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood pressure and pulse rate measurement with Dash 5000 patient monitoring system (GE Healthcare, USA) at 0 (before Metoprolol Tartrate 100 mg dosing), 1, 2, 3, 4, 5, 6, 8, 10, 12 hours after Metoprolol Tartrate 100 mg dosing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Hypertension</condition>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Sarpogrelate pretreatment and Metoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarpogrelate and Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol Tartrate 100 mg once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpogrelate pretreatment</intervention_name>
    <description>Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days</description>
    <arm_group_label>Sarpogrelate pretreatment and Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpogrelate</intervention_name>
    <description>Sarpogrelate hydrochloride 100 mg three times a day</description>
    <arm_group_label>Sarpogrelate pretreatment and Metoprolol</arm_group_label>
    <arm_group_label>Sarpogrelate and Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol Tartrate 100 mg once a day</description>
    <arm_group_label>Sarpogrelate pretreatment and Metoprolol</arm_group_label>
    <arm_group_label>Sarpogrelate and Metoprolol</arm_group_label>
    <arm_group_label>Metoprolol only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 20 - 45 years

          -  With in 20% of ideal body weight, {Ideal body weight=[height(cm)-100]*0.9}

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic,
             gastrointestinal disease or mental disorder (Past history or present)

          -  Inadequate result of laboratory test (especially, AST/ALT &gt; 1.25 x UNL, Total
             bilirubin &gt; 1.5 x UNL)

          -  Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL test

          -  Taking OTC(Over the counter)medicine including oriental medicine within 7 days

          -  Clinically significant allergic disease (Except for mild allergic rhinitis and
             dermatitis seems to be not need for medication)

          -  Subject with known for hypersensitivity reaction to Metoprolol or Sarpogrelate

          -  Previous whole blood donation within 60 days or component blood donation within 30
             days

          -  Previous participation of other trial within 90 days

          -  Continued taking caffeine (caffeine &gt; 5 cup/day), drinking (alcohol &gt; 30 g/day) and
             severe heavy smoker (cigarette &gt; 1/2 pack per day)

          -  An impossible one who participates in clinical trial by investigator's decision
             including for reason of laboratory test result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doo-Yeoun Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doo-Yeoun Cho, MD</last_name>
    <phone>+82-31-219-4271</phone>
    <email>dooycho@ajou.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <zip>433-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo-Yeoun Cho, MD</last_name>
      <phone>+82-31-219-4271</phone>
      <email>dooycho@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Doo-Yeoun Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Doo-Yeoun Cho</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
